Maged Shenouda bought $48k of RLMD
Chief Financial Officer at RELMADA THERAPEUTICS, INC.. 11,665 shares at an average of $4.12, traded Dec 15, 2025, filed Dec 16, 2025.
Score components
- +22RoleCFO
- +7Trade size$48k at market
- 0Relative to holdingsHoldings up 1.5%
- 0Price contextNear the top of the 52-week range
- +8Cluster2 insiders buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -15.6%, 3m +43.3%, 6m +45.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001213900-25-121973, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 15, 2025 | POpen-market purchase Common Stock | +11,665 | $4.12 | $48k | 800,000 | Dec 16, 2025 |
| Dec 12, 2025 | AGrant or award Stock Appreciation Rightsderivative | +828,000 | $0.00 | $0 | 828,000 | Dec 16, 2025 |
Related signals
Other insiders at RELMADA THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 59Moderate | RELMADA THERAPEUTICS, INC. | Sergio Traversa Chief Executive Officer | $828k 200,000 shares | +15% | |
| 59Moderate | RELMADA THERAPEUTICS, INC. | Maged Shenouda Chief Financial Officer | $844k 200,000 shares | +25% | |
| 48Moderate | RELMADA THERAPEUTICS, INC. | Sergio Traversa Chief Executive Officer | $113k 27,500 shares | +2% | |
| 63Notable | RELMADA THERAPEUTICS, INC. | Chuck Ence CAO and COO | $299k 136,000 shares | +51% | |
| 57Moderate | RELMADA THERAPEUTICS, INC. | Paul Edward Kelly Chief Operating Officer | $198k 90,000 shares | +22% | |
| 76Notable | RELMADA THERAPEUTICS, INC. | Maged Shenouda Chief Financial Officer | $1.1M 500,000 shares | +173% | |
| 74Notable | RELMADA THERAPEUTICS, INC. | Sergio Traversa Chief Executive Officer | $600k 272,500 shares | +27% | |
| 51Moderate | RLMDbuy RELMADA THERAPEUTICS, INC. | Sergio Traversa Chief Executive Officer | $178k 265,976 shares | +36% | |
| 58Moderate | RELMADA THERAPEUTICS, INC. | Chuck Ence CA and CO | $103k 228,961 shares | +588% | |
| 62Notable | RELMADA THERAPEUTICS, INC. | Paul Edward Kelly Chief Operating Officer | $86k 200,000 shares | +94% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.